Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Sell at StockNews.com

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at StockNews.com to a “sell” rating in a report issued on Thursday.

Several other analysts have also commented on the stock. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. Citigroup decreased their price target on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 24th. Wedbush reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. Finally, BMO Capital Markets lifted their price target on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $69.00.

Intellia Therapeutics Stock Down 3.5 %

Shares of NASDAQ:NTLA opened at $22.38 on Thursday. Intellia Therapeutics has a 52-week low of $19.37 and a 52-week high of $46.50. The stock has a market cap of $2.16 billion, a P/E ratio of -4.18 and a beta of 1.84. The business has a fifty day moving average of $23.76 and a two-hundred day moving average of $26.32.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.29. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. The firm had revenue of $28.94 million during the quarter, compared to analyst estimates of $15.60 million. On average, equities analysts anticipate that Intellia Therapeutics will post -4.98 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

Several hedge funds have recently modified their holdings of NTLA. Opaleye Management Inc. grew its stake in Intellia Therapeutics by 157.6% during the 1st quarter. Opaleye Management Inc. now owns 255,000 shares of the company’s stock worth $7,015,000 after purchasing an additional 156,000 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Intellia Therapeutics during the first quarter worth about $802,000. Comerica Bank increased its stake in shares of Intellia Therapeutics by 853.6% during the first quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after buying an additional 33,214 shares during the period. Bayesian Capital Management LP acquired a new stake in Intellia Therapeutics in the first quarter valued at approximately $303,000. Finally, Axxcess Wealth Management LLC lifted its stake in Intellia Therapeutics by 6.5% in the first quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock worth $457,000 after acquiring an additional 1,010 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.